Peptides for sexual and reproductive health, ranked by human evidence

Peptides studied for sexual function and the reproductive hormones — from approved fertility and melanocortin medicines to research compounds. They are ranked by an evidence score that weighs the grade of the evidence, the human trials counted in PubMed, and regulatory status — shown in the columns so any rank can be checked. A high score means a peptide is well studied and often approved for something, not that it is right, safe or legal for this goal. Nothing here is medical advice, and Grey Peptides sells nothing and links to no vendor. See all goals or the plainer browse by goal map.

Evidence grade

Regulatory status

Search name

Has a human trial on this page

47 peptides · sorted by evidence score (click a column to re-sort)

Peptide	Grade	Human studies	RCTs	Max trial phase	Regulatory	Dose	Score
Afamelanotide	High	437	8	Phase 3	FDA approved	subcutaneous implant →	100
Urofollitropin	High	239	59	Phase 4	FDA approved	—	100
Relugolix	High	191	32	Phase 4	FDA approved	oral →	100
Follitropin beta	High	180	59	Phase 4	FDA approved	subcutaneous →	100
Elagolix	High	145	26	Phase 4	FDA approved	oral →	100
PT-141	High	92	14	Phase 3	FDA approved	subcutaneous →	100
Menotropin	High	54,103	3,697	Phase 4	FDA approved	—	90
Oxytocin	High	17,006	2,151	Phase 4	FDA approved	—	90
Alprostadil	High	9,253	797	Phase 4	FDA approved	intracavernosal injection →	90
Leuprolide	High	3,328	563	Phase 4	FDA approved	—	90
Goserelin	High	1,887	437	Phase 4	FDA approved	subcutaneous implant (anterior abdominal wall, below the navel) →	90
Triptorelin	High	1,810	343	Phase 4	FDA approved	intramuscular →	90
Buserelin	High	1,781	271	Phase 4	Approved abroad	—	90
Follitropin alfa	High	1,321	83	Phase 4	FDA approved	—	90
Cetrorelix	High	553	112	Phase 4	FDA approved	subcutaneous →	90
Nafarelin	High	318	67	Phase 4	FDA approved	—	90
Degarelix	High	304	52	Phase 4	FDA approved	subcutaneous (abdomen) →	90
Ganirelix	High	282	77	Phase 4	FDA approved	subcutaneous (thigh or abdomen) →	90
Histrelin	High	135	2	Phase 3	FDA approved	subcutaneous implant (inner aspect of upper arm) →	90
Follitropin delta	High	67	21	Phase 4	Approved abroad	—	90
Abarelix	High	51	2	Phase 4	Withdrawn	intramuscular →	85
Atosiban	High	383	55	Phase 4	Approved abroad	intravenous →	80
Carbetocin	High	275	67	Phase 4	Approved abroad	IV or IM →	80
Corifollitropin alfa	High	122	33	Phase 4	Approved abroad	subcutaneous →	80
Kisspeptin-10	Medium	748	17	Phase 3	In trials	—	70
Teverelix	Medium	12	2	Phase 2	In trials	subcutaneous and intramuscular →	70
INSL3	Medium	486	7	—	Research only	—	65
Neurokinin B	Medium	476	14	Phase 3	Research only	—	65
Demoxytocin	Medium	80	5	—	Discontinued	buccal →	65
Deslorelin	Medium	55	27	Phase 3	Veterinary	—	65
Detirelix	Medium	5	1	—	Discontinued	subcutaneous →	65
Kisspeptin-54	Medium	1,231	29	Phase 3	In trials	—	60
Gonadorelin	Medium	24,018	2,458	Phase 4	Discontinued	intravenous or subcutaneous pump →	55
Lutropin alfa	Medium	2,526	294	Phase 4	Discontinued	subcutaneous →	55
Melanotan II	Medium	104	1	Phase 2	Research only	—	55
Avorelin	Low	1	1	—	Discontinued	subcutaneous →	45
Lecirelin	Low	0	6	—	Veterinary	—	45
Equine Chorionic Gonadotropin	Low	716	58	—	Veterinary	—	35
Prokineticin 1 (EG-VEGF)	Low	180	2	—	Research only	—	35
RFRP-3 (GnIH)	Low	86	3	—	Research only	—	35
Porcine FSH	Low	73	28	—	Veterinary	—	35
Phoenixin	Low	67	0	—	Research only	—	35
GnRF Analogue–Diphtheria Toxoid Conjugate	Low	7	20	—	Veterinary	—	35
Peforelin	Low	4	3	—	Veterinary	—	35
Azagly-nafarelin	Low	0	0	—	Veterinary	—	35
Gonadorelin (6-D-Phe)	Low	0	0	—	Veterinary	—	35
Ozarelix	Low	3	0	Phase 2	Approved abroad	—	30

Other goals: Weight loss and metabolism · Healing, injury and recovery · Skin and hair · Focus, mood and the brain · Growth hormone and body composition · Heart and circulation · Longevity and cell health · Immune defence and infection · Diagnostic and research tools · In development

How the evidence score works

Evidence score (0-100), a transparent ranking aid, not a verdict. grade: high=60, medium=40, low=20, ungraded=0. Human trial: an on-site read-and-cited randomized or clinical trial = +15, else any PubMed human-indexed record = +5, else 0. RCT literature: PubMed lists >=1 randomized controlled trial = +10. Regulatory: FDA-approved = +15, in trials / approved-abroad / in development = +5, else 0. Every component is stored on each record so the number can be re-derived; volume and grade are shown together so neither misleads.

“Human studies” and “RCTs” are PubMed record counts for the peptide (read 2026-11-07 from the counts behind the Evidence Explorer); a count is how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence — see how we grade evidence. The “Dose” column links to the entry for each peptide that carries a dose from a regulator’s label or a published human study — where the amount is shown with its source; the amount is never reprinted here without that source, and many research peptides have no human dose, shown as —. Of 660 peptides, 607 have at least one human-indexed PubMed record, 324 cite a human trial on their page, 124 are FDA-approved, and 271 carry a sourced dose.